GeNeuro begins treatment in Phase llb trial of GNbAC1 to treat RRMS

Swiss-based, biopharmaceutical company GeNeuro has started treating patients in a Phase IIb trial of GNbAC1 for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news